×
×

MOLECULAR BIOLOGY

Department of Molecular Biology

Μεταλλαγές των BRAF/NRAS σε υγρή βιοψία

Το BRAF/NRAS Mutation Test v2 (Roche Molecular Diagnostics), ανιχνεύει μεταλλαγές στα γονίδια BRAF και NRAS από το πλάσμα των ασθενών (υγρή βιοψία) ενώ μπορεί να χρησιμοποιηθεί υλικό και από τον καρκινικό ιστό, εξαλείφοντας συχνούς περιορισμούς στον μοριακό έλεγχο όπως η ανάγκη για χειρουργική επέμβαση και η ανεπάρκεια υλικού. Με ξεκάθαρα αποτελέσματα, παρέχει στους κλινικούς αξιόπιστη πληροφορία για τη λήψη θεραπευτικών αποφάσεων.

Verifi - Non Invasive Prenatal Testing

We proudly offer Illumina's verifi® prenatal test — a non-invasive prenatal test that detects multiple fetal chromosomal aneuploidies using a single maternal blood draw with near-diagnostic accuracy. If you have ever wanted safer, simpler test results or wished to screen at 10 weeks instead of waiting, now you can order the verifi® prenatal test.

Color

Ο Γενετικός Έλεγχος Κληρονομούμενου Καρκίνου Color

Ανακαλύψτε εάν διαθέτετε γενετική προδιάθεση για εμφάνιση των συχνότερων μορφών κληρονομικού καρκίνου.

Το γενετικό τεστ Color αναλύει 30 γονίδια – συμπεριλαμβανομένων των BRCA1 και BRCA2 – και βοηθάει γυναίκες και άνδρες να ανακαλύψουν εάν διατρέχουν σημαντικό κίνδυνο εμφάνισης των συχνότερων μορφών κληρονομικού καρκίνου, όπως ο καρκίνος του μαστού, των ωοθηκών, του παχέος εντέρου, του παγκρέατος κ.α.

Επιλέγοντας το Color

EGFR Mutations in Liquid Biopsies

The first CE-IVD test for EGFR Mutations in liquid biopsies

The cobas® EGFR Mutation Test v2 CE-IVD, identifies the epidermal growth factor receptor (EGFR) gene in the DNA from non-small cell lung cancer (NSCLC) patients and is intended to be used as an aid in selecting patients with NSCLC for therapy with an EGFR tyrosine kinase inhibitor (TKI).

MammaPrint - Agendia

MammaPrint Provides Individualized Metastasis Risk Assessment for Your Breast Cancer Patients

MammaPrint is the first FDA-cleared IVDMIA breast cancer recurrence assay. The unique 70-gene signature of MammaPrint provides you with the unprecedented ability to identify which early-stage breast cancer patients are at risk of distant recurrence following surgery, independent of Estrogen Receptor status and any prior treatment.

EGFR mutational analysis by Real-Time PCR

Approximately 10% of patients with NSCLC in the US and 35% in East Asia have tumor associated EGFR mutations. These mutations occur within EGFR exons 18–21, which encodes a portion of the EGFR kinase domain (Figure 1). EGFR mutations are usually heterozygous, with the mutant allele also showing gene amplification. Approximately 90% of these mutations are exon 19 deletions or exon 21 L858R point mutations. These mutations increase the kinase activity of EGFR, leading to hyperactivation of downstream pro-survival signaling pathways.

Ras family mutations (KRAS & NRAS)

Recent reserach indicates that the absence of activating mutations in KRAS and NRAS genes (exons 2, 3 and 4 for each gene) is necessary for the treatment of metastatic colorectal cancer with anti-EGFR antibodies.

Reference:

Peeters M, Oliner KS, Parker A, Siena S, Van Cutsem E, Huang J, Humblet Y, Van Laethem JL, André T, Wiezorek J, Reese D, Patterson SD. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin Cancer Res. 2013 Apr 1;19(7):1902-12.

Familial Breast / Ovarian Cancer Gene Panel (19 genes)

In about 15-20% of all breast cancer cases, patients present family history but are free of BRCA1 and BRCA2 genetic alterations. In this case, their cancer is termed familial. Recent research has revealed a number mutations in other genes, some rarely mutated but with high-penetrance and other more commonly mutated with individual low-penetrance but cumulative action, that increase the life time risk for developing breast cancer.

BRAF mutation analysis

General:

BRAF belongs to a family of serine-threonine protein kinases that includes ARAF, BRAF, and CRAF (RAF1). RAF kinases are central mediators in the MAP kinase signaling cascade and exert their effect predominantly through phosphorylation and activation of MEK. This occurs following the dimerization (hetero- or homo-) of the RAF molecules. As part of the MAP kinase pathway, RAF is involved in many cellular processes, including cell proliferation, differentiation, and transcriptional regulation.

CLART® STIs A&B

CLART® STIs A&B are products for in Vitro diagnostics used for the detection and typing of those bacteria, fungi and parasites causing urogenital tract infections. Detection is performed simultaneously by performing multiplex PCR and its subsequent visualization with CLART ® Technology, based on low-density microarrays.

 

Analysis information

Pages